{"id":7418,"date":"2016-08-10T05:31:07","date_gmt":"2016-08-10T05:31:07","guid":{"rendered":"https:\/\/www.nicox.com\/nicox-finalise-le-transfert-de-ses-operations-commerciales-une-nouvelle-societe-pharmaceutique-pan-europeenne-specialisee-dans-lophtalmologie-creee-par-gho-capital-2\/"},"modified":"2016-08-10T05:31:07","modified_gmt":"2016-08-10T05:31:07","slug":"nicox-finalise-le-transfert-de-ses-operations-commerciales-une-nouvelle-societe-pharmaceutique-pan-europeenne-specialisee-dans-lophtalmologie-creee-par-gho-capital-2","status":"publish","type":"post","link":"https:\/\/www.nicox.com\/fr\/nicox-finalise-le-transfert-de-ses-operations-commerciales-une-nouvelle-societe-pharmaceutique-pan-europeenne-specialisee-dans-lophtalmologie-creee-par-gho-capital-2\/","title":{"rendered":"Nicox finalise le transfert de ses op\u00e9rations commerciales \u00e0 une nouvelle soci\u00e9t\u00e9 pharmaceutique pan-europ\u00e9enne sp\u00e9cialis\u00e9e dans l\u2019ophtalmologie cr\u00e9\u00e9e par GHO Capital"},"content":{"rendered":"<p>Sophia Antipolis, France.<\/p>\n<p><strong>Nicox S.A<\/strong>. (Euronext Paris : FR0013018124, COX, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 internationale sp\u00e9cialis\u00e9e en ophtalmologie, annonce aujourd\u2019hui avoir finalis\u00e9 le transfert de son infrastructure commerciale europ\u00e9enne et internationale et son portefeuille associ\u00e9 de produits \u00e0 un stade de d\u00e9veloppement avanc\u00e9 \u00e0 une soci\u00e9t\u00e9 pharmaceutique pan-europ\u00e9enne priv\u00e9e, nouvellement cr\u00e9\u00e9e, sp\u00e9cialis\u00e9e dans l\u2019ophtalmologie. Cette transaction inclut les filiales Nicox Pharma (France) et les op\u00e9rations commerciales en Espagne et au Royaume-Uni, Nicox GmbH (Allemagne), Laboratoires Nicox (France) et Nicox Farma (Italie), tous les produits actuellement commercialis\u00e9s ainsi que les droits aff\u00e9rents (et les accords correspondants) \u00e0 AzaSite\u00ae, AzaSite Xtra\u00ae, BromSiteTM pour l\u2019Europe, le Moyen Orient et l\u2019Afrique et \u00e0 NCX 4240 en dehors du Japon et de l\u2019Am\u00e9rique du Nord. Aucune autre filiale de Nicox et aucun de ses programmes de R&amp;D n\u2019est inclus ou impact\u00e9 par cette transaction.<\/p>\n<p>Nicox recevra 9 millions d\u2019euros en num\u00e9raire de GHO Capital \u00e0 la finalisation de la transaction. Pour plus d\u2019information sur la transaction, voir communiqu\u00e9 de presse du 5 juillet 2016.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sophia Antipolis, France. Nicox S.A. (Euronext Paris : FR0013018124, COX, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 internationale sp\u00e9cialis\u00e9e en ophtalmologie, annonce aujourd\u2019hui avoir finalis\u00e9 le transfert de son infrastructure commerciale europ\u00e9enne et internationale et son portefeuille associ\u00e9 de produits \u00e0 un stade de d\u00e9veloppement avanc\u00e9 \u00e0 une soci\u00e9t\u00e9 pharmaceutique pan-europ\u00e9enne priv\u00e9e, nouvellement cr\u00e9\u00e9e, sp\u00e9cialis\u00e9e dans l\u2019ophtalmologie. Cette transaction [&hellip;]<\/p>\n","protected":false},"author":7,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[32,16],"tags":[],"class_list":["post-7418","post","type-post","status-publish","format-standard","hentry","category-actualites","category-actualites-et-media"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nicox finalise le transfert de ses op\u00e9rations commerciales \u00e0 une nouvelle soci\u00e9t\u00e9 pharmaceutique pan-europ\u00e9enne sp\u00e9cialis\u00e9e dans l\u2019ophtalmologie cr\u00e9\u00e9e par GHO Capital - Nicox<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.nicox.com\/fr\/nicox-finalise-le-transfert-de-ses-operations-commerciales-une-nouvelle-societe-pharmaceutique-pan-europeenne-specialisee-dans-lophtalmologie-creee-par-gho-capital-2\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nicox finalise le transfert de ses op\u00e9rations commerciales \u00e0 une nouvelle soci\u00e9t\u00e9 pharmaceutique pan-europ\u00e9enne sp\u00e9cialis\u00e9e dans l\u2019ophtalmologie cr\u00e9\u00e9e par GHO Capital - Nicox\" \/>\n<meta property=\"og:description\" content=\"Sophia Antipolis, France. Nicox S.A. (Euronext Paris : FR0013018124, COX, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 internationale sp\u00e9cialis\u00e9e en ophtalmologie, annonce aujourd\u2019hui avoir finalis\u00e9 le transfert de son infrastructure commerciale europ\u00e9enne et internationale et son portefeuille associ\u00e9 de produits \u00e0 un stade de d\u00e9veloppement avanc\u00e9 \u00e0 une soci\u00e9t\u00e9 pharmaceutique pan-europ\u00e9enne priv\u00e9e, nouvellement cr\u00e9\u00e9e, sp\u00e9cialis\u00e9e dans l\u2019ophtalmologie. Cette transaction [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.nicox.com\/fr\/nicox-finalise-le-transfert-de-ses-operations-commerciales-une-nouvelle-societe-pharmaceutique-pan-europeenne-specialisee-dans-lophtalmologie-creee-par-gho-capital-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Nicox\" \/>\n<meta property=\"article:published_time\" content=\"2016-08-10T05:31:07+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-finalise-le-transfert-de-ses-operations-commerciales-une-nouvelle-societe-pharmaceutique-pan-europeenne-specialisee-dans-lophtalmologie-creee-par-gho-capital-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-finalise-le-transfert-de-ses-operations-commerciales-une-nouvelle-societe-pharmaceutique-pan-europeenne-specialisee-dans-lophtalmologie-creee-par-gho-capital-2\\\/\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"Nicox finalise le transfert de ses op\u00e9rations commerciales \u00e0 une nouvelle soci\u00e9t\u00e9 pharmaceutique pan-europ\u00e9enne sp\u00e9cialis\u00e9e dans l\u2019ophtalmologie cr\u00e9\u00e9e par GHO Capital\",\"datePublished\":\"2016-08-10T05:31:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-finalise-le-transfert-de-ses-operations-commerciales-une-nouvelle-societe-pharmaceutique-pan-europeenne-specialisee-dans-lophtalmologie-creee-par-gho-capital-2\\\/\"},\"wordCount\":212,\"publisher\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\"},\"articleSection\":[\"Actualit\u00e9s\",\"Actualit\u00e9s et M\u00e9dia\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-finalise-le-transfert-de-ses-operations-commerciales-une-nouvelle-societe-pharmaceutique-pan-europeenne-specialisee-dans-lophtalmologie-creee-par-gho-capital-2\\\/\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-finalise-le-transfert-de-ses-operations-commerciales-une-nouvelle-societe-pharmaceutique-pan-europeenne-specialisee-dans-lophtalmologie-creee-par-gho-capital-2\\\/\",\"name\":\"Nicox finalise le transfert de ses op\u00e9rations commerciales \u00e0 une nouvelle soci\u00e9t\u00e9 pharmaceutique pan-europ\u00e9enne sp\u00e9cialis\u00e9e dans l\u2019ophtalmologie cr\u00e9\u00e9e par GHO Capital - Nicox\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#website\"},\"datePublished\":\"2016-08-10T05:31:07+00:00\",\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-finalise-le-transfert-de-ses-operations-commerciales-une-nouvelle-societe-pharmaceutique-pan-europeenne-specialisee-dans-lophtalmologie-creee-par-gho-capital-2\\\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/\",\"name\":\"Nicox\",\"description\":\"Visible Science\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\",\"name\":\"Nicox\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Nicox\"},\"image\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nicox finalise le transfert de ses op\u00e9rations commerciales \u00e0 une nouvelle soci\u00e9t\u00e9 pharmaceutique pan-europ\u00e9enne sp\u00e9cialis\u00e9e dans l\u2019ophtalmologie cr\u00e9\u00e9e par GHO Capital - Nicox","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.nicox.com\/fr\/nicox-finalise-le-transfert-de-ses-operations-commerciales-une-nouvelle-societe-pharmaceutique-pan-europeenne-specialisee-dans-lophtalmologie-creee-par-gho-capital-2\/","og_locale":"fr_FR","og_type":"article","og_title":"Nicox finalise le transfert de ses op\u00e9rations commerciales \u00e0 une nouvelle soci\u00e9t\u00e9 pharmaceutique pan-europ\u00e9enne sp\u00e9cialis\u00e9e dans l\u2019ophtalmologie cr\u00e9\u00e9e par GHO Capital - Nicox","og_description":"Sophia Antipolis, France. Nicox S.A. (Euronext Paris : FR0013018124, COX, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 internationale sp\u00e9cialis\u00e9e en ophtalmologie, annonce aujourd\u2019hui avoir finalis\u00e9 le transfert de son infrastructure commerciale europ\u00e9enne et internationale et son portefeuille associ\u00e9 de produits \u00e0 un stade de d\u00e9veloppement avanc\u00e9 \u00e0 une soci\u00e9t\u00e9 pharmaceutique pan-europ\u00e9enne priv\u00e9e, nouvellement cr\u00e9\u00e9e, sp\u00e9cialis\u00e9e dans l\u2019ophtalmologie. Cette transaction [&hellip;]","og_url":"https:\/\/www.nicox.com\/fr\/nicox-finalise-le-transfert-de-ses-operations-commerciales-une-nouvelle-societe-pharmaceutique-pan-europeenne-specialisee-dans-lophtalmologie-creee-par-gho-capital-2\/","og_site_name":"Nicox","article_published_time":"2016-08-10T05:31:07+00:00","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.nicox.com\/fr\/nicox-finalise-le-transfert-de-ses-operations-commerciales-une-nouvelle-societe-pharmaceutique-pan-europeenne-specialisee-dans-lophtalmologie-creee-par-gho-capital-2\/#article","isPartOf":{"@id":"https:\/\/www.nicox.com\/fr\/nicox-finalise-le-transfert-de-ses-operations-commerciales-une-nouvelle-societe-pharmaceutique-pan-europeenne-specialisee-dans-lophtalmologie-creee-par-gho-capital-2\/"},"author":{"name":"","@id":""},"headline":"Nicox finalise le transfert de ses op\u00e9rations commerciales \u00e0 une nouvelle soci\u00e9t\u00e9 pharmaceutique pan-europ\u00e9enne sp\u00e9cialis\u00e9e dans l\u2019ophtalmologie cr\u00e9\u00e9e par GHO Capital","datePublished":"2016-08-10T05:31:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.nicox.com\/fr\/nicox-finalise-le-transfert-de-ses-operations-commerciales-une-nouvelle-societe-pharmaceutique-pan-europeenne-specialisee-dans-lophtalmologie-creee-par-gho-capital-2\/"},"wordCount":212,"publisher":{"@id":"https:\/\/www.nicox.com\/fr\/#organization"},"articleSection":["Actualit\u00e9s","Actualit\u00e9s et M\u00e9dia"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.nicox.com\/fr\/nicox-finalise-le-transfert-de-ses-operations-commerciales-une-nouvelle-societe-pharmaceutique-pan-europeenne-specialisee-dans-lophtalmologie-creee-par-gho-capital-2\/","url":"https:\/\/www.nicox.com\/fr\/nicox-finalise-le-transfert-de-ses-operations-commerciales-une-nouvelle-societe-pharmaceutique-pan-europeenne-specialisee-dans-lophtalmologie-creee-par-gho-capital-2\/","name":"Nicox finalise le transfert de ses op\u00e9rations commerciales \u00e0 une nouvelle soci\u00e9t\u00e9 pharmaceutique pan-europ\u00e9enne sp\u00e9cialis\u00e9e dans l\u2019ophtalmologie cr\u00e9\u00e9e par GHO Capital - Nicox","isPartOf":{"@id":"https:\/\/www.nicox.com\/fr\/#website"},"datePublished":"2016-08-10T05:31:07+00:00","inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.nicox.com\/fr\/nicox-finalise-le-transfert-de-ses-operations-commerciales-une-nouvelle-societe-pharmaceutique-pan-europeenne-specialisee-dans-lophtalmologie-creee-par-gho-capital-2\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.nicox.com\/fr\/#website","url":"https:\/\/www.nicox.com\/fr\/","name":"Nicox","description":"Visible Science","publisher":{"@id":"https:\/\/www.nicox.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.nicox.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.nicox.com\/fr\/#organization","name":"Nicox","url":"https:\/\/www.nicox.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.nicox.com\/fr\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Nicox"},"image":{"@id":"https:\/\/www.nicox.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":""}]}},"_links":{"self":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts\/7418","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/comments?post=7418"}],"version-history":[{"count":0,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts\/7418\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/media?parent=7418"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/categories?post=7418"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/tags?post=7418"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}